Webinar Date/Time: Tue, Jan 24, 2023 11:00 AM EST
Intensify the inoculation of large-scale bioreactors with a new seed train benchtop module. Discover a CDMO’s experience using the module for low-risk and cost-effective viral production.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1588661&tp_key=a5faada3f1
Event Overview:
The use of adherent-cell cultures for commercial manufacture of advanced therapies requires inoculating large-scale bioreactors with vast amounts of cells. Traditional cell-expansion systems such as plastic flatware are still used for this purpose, but are generally associated with significant aseptic risk, footprint, and production costs. Univercells Technologies has designed a novel benchtop solution to tackle these challenges, delivering reliable, automated, and intensified seed train. Discover how a CDMO has used this new technology, achieving harvest cell densities above 2x109 cells/m² with >90% cell detachment in a small-footprint, low-risk, and cost-effective seed train process.
Key Learning Objectives:
Speakers:
Clément Dumont
Product Manager
Univercells Technology
Clément Dumont, product manager at Univercells Technologies, focuses on the expansion of the scale-X portfolio with intensified bioreactor systems and innovative process analytical technologies. He has experience in the areas of bioprocess development, characterization, and optimization, which he currently applies to the development of the scale-X cell collect module for seed train generation. Clément also has product management experience in the field of medical devices and holds a master’s degree in biomedical engineering from the UCLouvain, Belgium.
Cédric Meeüs
Bioprocess Engineer
Exothera
During his studies (Master’s Degree in Industrial Engineering in Pharmaceutical Biotechnology), Cédric Meeüs joined Univercells to support his thesis regarding the validation and design of the soon-to-be scale-X™ carbo. He then remained in the company and joined its process development team, taking charge of upstream bioprocessing and validating the scale-X carbo and nitro bioreactor systems. Cédric has since joined Exothera and has gathered a wide knowledge of scale-X technology. He also specializes in the areas of gene therapy, viral vectors, recombinant proteins, and the adaptation of suspension cells to fixed-bed bioreactors.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1588661&tp_key=a5faada3f1
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.